tiprankstipranks
Trending News
More News >
Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
US Market
Advertisement

Nautilus Biotechnolgy (NAUT) AI Stock Analysis

Compare
141 Followers

Top Page

NAUT

Nautilus Biotechnolgy

(NASDAQ:NAUT)

Rating:41Neutral
Price Target:
Nautilus Biotechnology's score reflects its early-stage status with high operational losses and zero revenue, typical for biotech firms focused on R&D. While its strong cash reserves and low leverage offer some stability, persistent losses and slow pharma partnerships pose significant risks. Technical indicators suggest a bearish trend, but the earnings call highlighted positive advancements in proteomics and cost efficiencies, offering a cautiously optimistic outlook.
Positive Factors
Financial Stability
Cash runway is expected to extend well into '27.
Product Development
Management highlighted the recent proteoform product success with tau, increasing customer interest, and confidence in ongoing product development for the more important proteome platform.
Technical Advancement
Management was positive on continued technical advancement of the platform with the late '26 commercial launch timeline reiterated.
Negative Factors
Commercial Launch Delay
NAUT traded down nearly (20%) after another commercial launch timeline delay, this one a push out to late 2026.
Milestone Setbacks
The company was behind on internal milestones with respect to a major broadscale goal of quantifying a significant number of proteins from a complex sample.
Timeline Delays
NAUT announced its delaying timelines for its planned proteome analysis platform launch to late 2026.

Nautilus Biotechnolgy (NAUT) vs. SPDR S&P 500 ETF (SPY)

Nautilus Biotechnolgy Business Overview & Revenue Model

Company DescriptionNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.
How the Company Makes MoneyNautilus Biotechnology generates revenue primarily through the commercialization of its proteomics platform. The company offers its technology to pharmaceutical companies, academic institutions, and research organizations, which use it to conduct detailed protein analysis. Key revenue streams include the sale of instruments, consumables, and related services required to operate the platform. Additionally, Nautilus may engage in strategic partnerships and collaborations with other entities in the biotech and pharmaceutical industries, which can provide further revenue through joint research projects, licensing agreements, and milestone payments based on the successful achievement of specific research or development goals.

Nautilus Biotechnolgy Earnings Call Summary

Earnings Call Date:Jul 31, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 04, 2025
Earnings Call Sentiment Positive
The earnings call reflects a positive sentiment overall, as Nautilus Biotechnology achieved significant scientific milestones, established strategic collaborations, and demonstrated strong financial management. However, there are challenges in terms of market development for proteoforms and limited immediate revenue generation from current collaborations.
Q2-2025 Updates
Positive Updates
Significant Scientific Milestone Achieved
Nautilus publicly shared its first preprint featuring novel data using the Nautilus platform, showcasing unprecedented dynamic range and industry-leading reproducibility in proteoform data.
Proteoform Analysis Breakthrough
The Nautilus platform demonstrated the ability to measure proteoforms at a single molecule level, offering insights into tau biology and potential advancements in neurodegenerative disease diagnostics and therapeutics.
Successful Collaborations Established
Nautilus signed two collaborations with major U.S. research institutes to demonstrate platform capabilities and enable new biological insights in Alzheimer's disease.
Strong Financial Management
Operating expenses for Q2 2025 were $17.1 million, an 18% decrease from the same period in 2024, with a net loss of $15.0 million compared to $18.0 million in the prior year.
Solid Cash Position
The company ended the quarter with approximately $179.5 million in cash, cash equivalents, and investments, projecting a cash runway through 2027.
Negative Updates
Market Development Required for Proteoforms
The proteoform opportunity will require significant market development, as it introduces a fundamentally new measurement capability not previously available.
Limited Immediate Revenue from Collaborations
Current collaborations are not intended to generate revenue initially but to lay the foundation for future revenue opportunities.
Company Guidance
In the second quarter of 2025, Nautilus Biotechnology achieved significant milestones, notably through the release of a manuscript demonstrating their platform's ability to resolve proteoforms with high resolution and reproducibility. The platform showed a median coefficient of variation (CV) of 1.5% within experiments and around 5% across different setups, compared to up to 80% in existing methods. The assay displayed sensitivity to changes in proteoform abundance by a factor of over 1,000, and accurately quantified low-abundance forms, such as tau present at 0.1% of total tau. Nautilus also noted a decrease in operating expenses to $17.1 million, an 18% reduction from the previous year, with a net loss of $15 million. The company maintains a strong cash position of approximately $179.5 million, projecting a cash runway through 2027. Nautilus continues to focus on refining their broadscale assay and expanding collaborations, having signed two agreements with major U.S. research institutes.

Nautilus Biotechnolgy Financial Statement Overview

Summary
Nautilus Biotechnology is in an early growth phase with consistent zero revenue and significant net losses, typical for biotech startups. Strong cash reserves and low leverage offer some financial stability, but the ongoing operational losses and cash outflows pose significant risks.
Income Statement
15
Very Negative
Nautilus Biotechnology has consistently reported zero revenue, reflecting its early-stage development status typical for biotech firms. The company faces significant net losses, with a negative net profit margin and no gross profit. Revenue growth is non-existent, while operating expenses remain high, adversely affecting EBIT and EBITDA margins.
Balance Sheet
30
Negative
The balance sheet shows a relatively strong equity position with a consistent decrease in stockholders' equity over recent years, reflecting ongoing losses. The debt-to-equity ratio is favorable, indicating low leverage, but the negative equity in earlier years signals financial instability. The equity ratio is reasonably high, suggesting a good proportion of assets financed by equity.
Cash Flow
20
Very Negative
The cash flow statement reveals negative free cash flow and operating cash flow, reflecting high cash burn typical for biotech startups. The free cash flow to net income ratio is negative, indicating cash outflows exceed inflows. However, substantial cash reserves provide a buffer against short-term financial challenges.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue9.60M0.000.000.000.000.00
Gross Profit-70.00K-6.35M-5.71M-3.42M-2.84M-2.35M
EBITDA-68.60M-64.43M-74.30M-60.20M-47.66M-13.40M
Net Income-65.69M-70.78M-63.67M-57.92M-50.31M-15.62M
Balance Sheet
Total Assets213.19M242.74M305.56M350.05M398.45M85.01M
Cash, Cash Equivalents and Short-Term Investments147.87M129.89M173.42M184.47M345.73M76.74M
Total Debt28.18M30.48M34.63M30.33M30.03M4.78M
Total Liabilities32.09M34.01M40.21M35.13M34.87M114.73M
Stockholders Equity181.09M208.73M265.35M314.92M363.58M-29.72M
Cash Flow
Free Cash Flow-56.29M-61.27M-54.15M-48.13M-41.51M-14.92M
Operating Cash Flow-54.71M-59.15M-51.71M-45.81M-39.24M-14.00M
Investing Cash Flow63.59M66.25M-43.73M-25.74M-138.96M-25.28M
Financing Cash Flow693.00K1.14M368.00K562.00K327.45M75.90M

Nautilus Biotechnolgy Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.66
Price Trends
50DMA
0.73
Negative
100DMA
0.74
Negative
200DMA
1.17
Negative
Market Momentum
MACD
-0.02
Positive
RSI
39.57
Neutral
STOCH
23.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAUT, the sentiment is Negative. The current price of 0.66 is below the 20-day moving average (MA) of 0.69, below the 50-day MA of 0.73, and below the 200-day MA of 1.17, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 39.57 is Neutral, neither overbought nor oversold. The STOCH value of 23.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAUT.

Nautilus Biotechnolgy Risk Analysis

Nautilus Biotechnolgy disclosed 69 risk factors in its most recent earnings report. Nautilus Biotechnolgy reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Nautilus Biotechnolgy Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.92B-0.43-41.67%2.21%22.29%-1.85%
49
Neutral
$113.24M-25.25%12.13%-8.23%
47
Neutral
$148.38M-313.82%41.61%-17.39%
41
Neutral
$82.33M-31.55%6.27%
$90.85M-15.23%
34
Underperform
$204.68M-51.74%29.72%
33
Underperform
$263.97M-89.37%9.84%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
NAUT
Nautilus Biotechnolgy
0.66
-2.00
-75.19%
XBIT
XBiotech
2.92
-3.75
-56.22%
OBIO
Orchestra BioMed Holdings
2.75
-2.76
-50.09%
SEER
Seer
2.10
0.48
29.63%
TIL
Instil Bio
31.50
9.51
43.25%
NMRA
Neumora Therapeutics, Inc.
1.68
-9.73
-85.28%

Nautilus Biotechnolgy Corporate Events

Executive/Board ChangesBusiness Operations and StrategyFinancial Disclosures
Nautilus Biotechnology Announces Board Changes for 2025
Negative
Feb 27, 2025

Nautilus Biotechnology announced changes in its board of directors for the 2025 annual meeting, with Vijay Pande and Michael Altman stepping down, and Matthew McIlwain transitioning to a Class I director to maintain board balance. The company also reported its financial results for the fourth quarter and fiscal year 2024, highlighting a slight increase in operating expenses and a net loss compared to the previous year. Nautilus plans to launch its proteome analysis platform in late 2026 and has reduced its workforce by 16% to align resources with development goals, aiming to extend its cash runway through 2027.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 30, 2025